JS
Therapeutic Areas
Athebio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Athebody® DARPins for Targeted Radioligands (with POINT Biopharma) | Oncology (Solid Tumors) | Pre-clinical |
| Athebody® DARPins for pHLA-binding T-Cell Engagers | Oncology | Pre-clinical |
| Athebody® DARPins for Targeted AAV/LNP Delivery | Genetic Diseases / Targeted Delivery | Pre-clinical |
Leadership Team at Athebio
TH
Thomas Huber
Chief Executive Officer (CEO)
SM
Samuel Moser
Chief Operating Officer (COO)
PF
Patrik Forrer
Chairman & Co-Founder
JS
Joachim Schnabl
Co-founder & VP Digital Solutions
BK
Bernd Kinzel
Head of Pharmacology
TK
Torsten Kuiper
Head of Protein Science
JU
Johannes Urban
Head of Discovery
RW
Richard Woods
Head of Projects
SM
Sandra Meier
Operations Manager
DJ
Dr. Jens Hennecke
Board Member & Business Advisor